Valneva SE has grown revenue −22% a year over three years and 9.6% a year over five. Revenue growth, 3-year annual rate: −22% (Biotechnology median +17%). Revenue growth, 5-year rate: +9.6%, growth has slowed since the five-year average. Years of annual history on file: 7, FY2019 to FY2025, as filed.

VALNValneva SE

Healthcare

$5.72-48% 1Y

$5.72

$4.7852 weeks$11.99

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−76.2 points).

1 to watch, 1 neutral, 1 without data

Revenue trend+3% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction−76.2 points operating

Trailing-twelve-month operating margin, -54.9% now against 21.3% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is VALN growing?

Valneva SE has grown revenue −22% a year over three years and 9.6% a year over five.

−22%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +9.6%
Revenue growth, 5-year rate · −22% over three · growth has slowed since the five-year average
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›